Summary
Nanocurcumin has reached Preclinical as its most advanced recorded development stage across any indication, and the database holds no approval for COPD. No registered clinical trial in this database tests Nanocurcumin specifically in COPD. The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study. The literature layer holds 3 publications for this pair: 2 Cochrane reviews and 1 clinical trial publication. Publication years run from 2024 to 2025. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Chronic Obstructive Pulmonary Disease ranks 505 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Effectively zero — airflow obstruction is irreversible by definition in COPD; FEV1 decline continues at 30-60 mL/year on standard care.
Evidence table
| Evidence tier | C · Preliminary |
|---|---|
| Evidence score | 17.0 (trials 0.0, literature 12.0, tier 5, approved bonus 0.0) |
| Registered trials | 0 total: 0 recruiting, 0 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 3 (2 Cochrane reviews, 1 clinical trial publication) |
| Agent type | Supplement (Nutraceutical) |
| Development stage (any indication) | Preclinical |
| Mechanism / class | Herbal medicine for COPD · Halma MTJ, Saleeby Y, Tuszynski J · 2024 |
| Data sources | OSMF Chronic Disease Review |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
No registered trial links Nanocurcumin to COPD in the current OSMF trial extract.
Published literature
- Cochrane review Comparative Efficacy of Nutritional Supplements in Modulating Lung Function and Exercise Capacity in COPD Patients: A Network Meta-AnalysisZeng Y, He T, Ma X et al. · International journal of chronic obstructive pulmonary disease · 2025 · PMID 40401105
- Cochrane review The effects of various nutritional supplements in patients with chronic obstructive pulmonary disease: a network meta-analysisZeng J, Cheng J, Zhu L et al. · BMC pulmonary medicine · 2025 · PMID 40340688
- Clinical trial publication Nanocurcumin supplementation improves pulmonary function in severe COPD patients: A randomized, double blind, and placebo-controlled clinical trialZare'i M, Rabieepour M, Ghareaghaji R et al. · Phytotherapy research : PTR · 2024 · PMID 38178561
Mechanism and notes
Recorded mechanism or class: Herbal medicine for COPD · Halma MTJ, Saleeby Y, Tuszynski J · 2024.
OSMF's existing evidence tier for this pair is C (Preliminary), derived from the strength of the disease association recorded in OSMF Chronic Disease Review. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Nanocurcumin approved for COPD?
Nanocurcumin has reached Preclinical as its most advanced recorded development stage across any indication, and the database holds no approval for COPD. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Nanocurcumin in clinical trials for COPD?
No registered clinical trial in this database tests Nanocurcumin specifically in COPD. The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study.
What does the evidence show for Nanocurcumin in COPD?
Synthesis-level literature links Nanocurcumin to COPD, but no registered trial in this database tests the pair, so the evidence is observational, pooled from other indications, or pre-dates registry practice. OSMF's existing evidence tier for this pair is C (Preliminary), derived from the strength of the disease association recorded in OSMF Chronic Disease Review. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.